{rfName}
Ad

Indexed in

License and use

Citations

1

Altmetrics

Analysis of institutional authors

Share

January 13, 2025
Publications
>
Article
No

Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse.

Publicated to:Cancers. 17 (1): - 2025-01-05 17(1), DOI: 10.3390/cancers17010143

Authors: Martinez-Recio S; Molina-Pérez MA; Muñoz-Couselo E; Sevillano-Tripero AR; Aya F; Arance A; Orrillo M; Martin-Liberal J; Fernandez-Morales L; Lesta R; Quindós-Varela M; Nieva M; Vidal J; Martinez-Perez D; Barba A; Majem M

Affiliations

Department of Medical Oncology, Hospital Central de Asturias (HUCA), 33011 Oviedo, Spain. - Author
Department of Medical Oncology, Hospital Clínic, 08036 Barcelona, Spain. - Author
Department of Medical Oncology, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Spain. - Author
Department of Medical Oncology, Hospital del Mar-Parc Salut Mar, 08003 Barcelona, Spain. - Author
Department of Medical Oncology, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain. - Author
Department of Medical Oncology, Hospital Universitario de A Coruña (CHUAC), 15006 Coruña, Spain. - Author
Department of Medical Oncology, Hospital Universitario de Getafe, 28905 Madrid, Spain. - Author
Department of Medical Oncology, Hospital Universitario Vall d'Hebron, Vall d'Hebron Instute of Oncology (VHIO), 08035 Barcelona, Spain. - Author
Department of Medical Oncology, Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. - Author
See more

Abstract

Keywords

Adjuvant immunotherapyMelanomaPatterns of relapsePrognostic factorsSurvival outcomes

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancers due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 78/322, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-03:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 13 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as: